Collectively, recent advances in HCC immunotherapy focus on allogeneic GPC-3.CAR Vδ1 T cells expressing sIL-15, demonstrating tumor-specific activation and effective growth control [33]. This evidence concerns the gene GPC3 and neoplasm.